Pega-One logo


Established 2019

Jean-Pierre Armand, MD, PhD
Aurélien Marabelle, MD, PhD
Jean-Pierre Sommadossi, PhD

Pega-One was created to identify and develop oncology medicines in areas of high unmet need. The first asset, imgatuzumab, is an anti-EGFR tumor-targeting monoclonal antibody (mAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) properties licensed from Roche.

Pega-One is initially developing imgatuzumab as an investigational agent for the treatment of cutaneous squamous cell carcinoma (CSCC). Pega-One is also exploring imgatuzamab’s potential in combination with either immunotherapy or small molecules across multiple oncology indications.

Your browser is out-of-date!

Update your browser to view this website correctly. Outdated Browser